Fecal microbiota transplantation improved gut barrier function, mucosal immunity and ammonia metabolism in patients with cirrhosis, which could reduce hepatic encephalopathy and other infections, according to data from the PROFIT trial.
“Patients with cirrhosis have enteric dysbiosis,” Lindsey A. Edwards, BSC, MSc, PhD, research director of fecal microbiota transplant program at
Fecal microbiota transplant (FMT) promotes restoration of the gut microbiota, enzymes, and immune responses, and reduces ammonia build-up in patients with cirrhosis, a pilot study found.
People with signs of the most advanced liver disease should see a hepatologist, experts say, while primary care clinicians can effectively treat lower-risk cases.
In patients with gliomas bearing IDH1/2 mutations, the brain barrier-crossing oral drug vorasidenib kept tumors at bay, and could be used instead of more toxic chemotherapies and radiation.